Wall Street Zen Upgrades Pfizer (NYSE:PFE) to Buy

Key Points

• Wall Street Zen upgraded Pfizer to Buy from Hold.
• Analyst sentiment overall remains cautious: MarketBeat reports a consensus Hold rating from 22 analysts and an average price target of $30.32.
• Pfizer beat quarterly estimates, reporting earnings of $0.87 per share versus $0.74 expected and revenue of $16.58 billion versus $15.85 billion expected; revenue was down 0.4% year over year.

Pfizer (NYSE:PFE - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Saturday, Wall Street Zen reports.

Other analysts have also issued reports about the company. Freedom Broker boosted their target price on Pfizer from $33.00 to $34.00 and gave the company a "buy" rating in a research report on Friday, November 6th. Cantor Fitzgerald increased their price target on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Thursday, October 8th. Scotiabank raised their price objective on Pfizer from $33.00 to $35.00 and gave the company a "sector outperform" rating in a research note on Wednesday, November 4th. DZ Bank cut Pfizer from a "buy" rating to a "hold" rating in a research note on Friday, November 6th. Finally, Citigroup boosted their price objective on Pfizer from $27.00 to $30.00 and gave the company a "neutral" rating in a report on Wednesday, November 4th. Six research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $30.32.

Pfizer Trading Up 0.2%

NYSE:PFE opened at $28.89 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.10 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $164.65 billion, a price-to-earnings ratio of 9.45, a PEG ratio of 1.89 and a beta of 0.31. The firm has a fifty day simple moving average of $28.80 and a two-hundred day simple moving average of $26.98. Pfizer has a 12 month low of $23.62 and a 12 month high of $31.44.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.13. The firm had revenue of $16.58 billion during the quarter, compared to the consensus estimate of $15.85 billion. Pfizer had a net margin of 6.34% and a return on equity of 19.88%. The business's revenue was down .4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.87 earnings per share. Analysts expect that Pfizer will post 3.04 EPS for the current fiscal year.

Institutional Trading of Pfizer

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its position in shares of Pfizer by 6.3% during the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company's stock valued at $12,754,464,000 after buying an additional 31,412,883 shares during the last quarter. State Street Corp raised its position in Pfizer by 1.8% in the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company's stock valued at $7,394,749,000 after buying an additional 5,501,032 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Pfizer by 7.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 57,879,546 shares of the biopharmaceutical company's stock valued at $1,393,739,000 after acquiring an additional 3,999,646 shares in the last quarter. Bank of America Corp DE bought a new position in Pfizer during the 2nd quarter valued at $1,049,602,000. Finally, Dimensional Fund Advisors LP boosted its holdings in Pfizer by 0.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company's stock worth $1,022,606,000 after acquiring an additional 293,029 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

More Pfizer News

Here's some of the latest news about PFE:

• Positive Sentiment: Pfizer raised its 2026 revenue forecast by $1.5 billion, a constructive outlook signal. The company had also beaten Q3 earnings and revenue expectations, though investors did not respond positively to the results. Pfizer Just Raised Its 2026 Revenue Forecast by $1.5 Billion
• Negative Sentiment: Pfizer will stop selling Premarin hormone therapy in Canada after an internal review, adding to existing menopause-drug shortages and removing a product from that market. Pfizer to Stop Selling Premarin Hormone Therapy in Canada
• Negative Sentiment: Expanded patent litigation over the lipid-nanoparticle technology used in Pfizer and BioNTech’s COVID-19 vaccine could create legal liabilities or licensing costs. Could Expanded Patent Lawsuits Change the Bull Case?

Pfizer Company Profile

Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company's products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.